Lytgobi Interactions
There are 179 drugs known to interact with Lytgobi (futibatinib), along with 2 disease interactions, and 1 alcohol/food interaction. Of the total drug interactions, 31 are major, 144 are moderate, and 4 are minor.
- View all 179 medications that may interact with Lytgobi
- View Lytgobi alcohol/food interactions (1)
- View Lytgobi disease interactions (2)
Most frequently checked interactions
View interaction reports for Lytgobi (futibatinib) and the medicines listed below.
- Actimmune (interferon gamma-1b)
- Adcetris (brentuximab)
- Adcirca (tadalafil)
- Adzynma (apadamtase alfa, recombinant)
- Aimovig (erenumab)
- Alyftrek (deutivacaftor / tezacaftor / vanzacaftor)
- ambrisentan
- amlodipine
- Amondys 45 (casimersen)
- Amvuttra (vutrisiran)
- apremilast
- Attruby (acoramidis)
- Aubagio (teriflunomide)
- Augtyro (repotrectinib)
- Austedo XR (deutetrabenazine)
- Bafiertam (monomethyl fumarate)
- Benlysta (belimumab)
- Biktarvy (bictegravir / emtricitabine / tenofovir alafenamide)
- Bimzelx (bimekizumab)
- Blincyto (blinatumomab)
- bosentan
- Braftovi (encorafenib)
- Breyanzi (lisocabtagene maraleucel)
- Brilinta (ticagrelor)
- Brineura (cerliponase alfa)
- Briumvi (ublituximab)
- Brukinsa (zanubrutinib)
- Bylvay (odevixibat)
- Cabenuva (cabotegravir / rilpivirine)
- Cablivi (caplacizumab)
Lytgobi alcohol/food interactions
There is 1 alcohol/food interaction with Lytgobi (futibatinib).
Lytgobi disease interactions
There are 2 disease interactions with Lytgobi (futibatinib) which include:
Report options
More about Lytgobi (futibatinib)
- Lytgobi consumer information
- Compare alternatives
- Pricing & coupons
- Imprints, shape & color data
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: multikinase inhibitors
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Pemazyre
Pemazyre is used to treat certain types of bile duct cancer and myeloid/lymphoid neoplasms ...
Alecensa
Alecensa (alectinib) is an oral kinase inhibitor that may be used to treat certain types of ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Alunbrig
Alunbrig (brigatinib) is used to treat anaplastic lymphoma kinase-positive (ALK+) metastatic ...
Augtyro
Augtyro (repotrectinib) is a next-generation TKI (Tyrosine Kinase Inhibitor) cancer medicine used ...
Ayvakit
Ayvakit (avapritinib) is a prescription medicine used for the treatment of gastrointestinal stromal ...
Balversa
Balversa (erdafitinib) is an oral kinase inhibitor that may be used to treat adults with locally ...
Braftovi
Braftovi is a targeted cancer treatment used in combination with Mektovi, mFOLFOX6, or Erbitux, to ...
Cabometyx
Cabometyx is used to treat advanced kidney cancer, liver cancer, thyroid cancer, and pancreatic and ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.